Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 3

CALLISTO PHARMACEUTICALS INC

Form 3 April 25, 2007

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

OF Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement CALLISTO PHARMACEUTICALS INC [KAL] A Denoyer Bernard (Month/Day/Year) 04/12/2007 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O CALLISTO (Check all applicable) PHARMACEUTICALS, INC.. 420 LEXINGTON 10% Owner Director **AVENUE, SUITE 1609** _X__ Officer Other (give title below) (specify below) (Street) 6. Individual or Joint/Group Vice President, Finance Filing(Check Applicable Line) _X_ Form filed by One Reporting NEW YORK, NYÂ 10170 Person Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) (Instr. 5) Form: Direct (D) or Indirect (Instr. 5) Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

information contained in this form are not required to respond unless the form displays a

currently valid OMB control number.

3. Title and Amount of 1. Title of Derivative Security 2. Date Exercisable and 5. 6. Nature of Indirect 4. **Expiration Date** Securities Underlying Conversion Ownership Beneficial Ownership (Instr. 4) (Month/Day/Year) **Derivative Security** or Exercise Form of (Instr. 5) (Instr. 4) Price of Derivative Derivative Security:

Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Options	(1)	01/14/2014	Common Stock	100,000	\$ 3.6	D	Â
Stock Options	(2)	07/29/2015	Common Stock	75,000	\$ 1.38	D	Â
Stock Options	(3)	04/12/2017	Common Stock	75,000	\$ 0.66	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Denoyer Bernard C/O CALLISTO PHARMACEUTICALS, INC. 420 LEXINGTON AVENUE, SUITE 1609 NEW YORK Â NYÂ 10170	Â	Â	Vice President, Finance	Â		

Signatures

Bernard
Denoyer

**Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 30,000 options vest on 10/1/2004; 30,000 options vest on 1/15/2006; and 40,000 options vest on 1/15/2007
- (2) 25,000 options vest on each of 7/29/2006, 7/29/2007 and 7/29/2008.
- (3) 25,000 options vest on each of 4/12/2008, 4/12/2009 and 4/12/2010

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2